-
1 Comment
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, Protagenic Therapeutics, Inc. Common Stock gets an overall score of 1/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US74365N1037 |
Sector | Healthcare |
Industry | Biotechnology |
Beta | 0.35 |
---|---|
Market Cap | 2M |
PE Ratio | None |
Target Price | 4 |
Dividend Yield | None |
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PTIX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025